Click on the titles below
for a CME/CEU activity:
Multiple Myeloma: What Managed
Care Needs To Know
Multiple Myeloma (MM) accounts for
10% of hematologic malignancies. In 2007, it is
estimated that MM was responsible for 11,000 new deaths.
This cancer is more prevalent in African Americans than
Caucasians with a median age of 66 at diagnosis. As with
all cancers, early detection and treatment are necessary
for optimal patient outcomes. Managed care medical
directors and physician executives need to be and stay
informed on the diagnosis and treatments to appropriate
manage their population.
CME Valid to December 31, 2010
Targeted Therapies
in Non Small Cell Lung Cancer
Despite progress in early detection and treatment, NSCLC is often
diagnosed at an advanced stage and prognosis is poor. Historically,
treatment has included a variety of modalities such as surgery,
chemotherapy, and radiotherapy. More recently, therapeutic options
for NSCLC have evolved to include targeted agents such as
vinorelbine, paclitaxel, gemcitabine, docetaxel, pemetrexed,
bevacizumab, and erlotinib. The expanding role of the targeted
therapies and the concept of tailoring therapies based on clinical
and molecular markers are transforming the treatment of NSCLC. It is
imperative that oncologists, medical directors and nurses are
informed about these new treatments and how they can be combined and
used with current treatment regimens. During this session on
non-small cell lung cancer, medical directors and nurse case
managers will learn about these targeted therapies and the best way
to include them into their treatment regimens.
CME Valid to
December 31, 2010
